Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07543120 · ClinicalTrials.gov registry record · Phase 2
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT07543120: Recruiting Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT07543120 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 323 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07543120, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
Primary Outcome
Number of participants with Adverse events (AEs), including abnormal safety laboratory parameters and vital signs
Interventions
- DRUG QCZ484
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2026-05-07 |
| Est. Completion | 2031-11-30 |
| Phase | Phase 2 |
What NCT07543120 shows while recruiting
NCT07543120 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (143% higher).
The record links to 0 conditions, and to 1 intervention - of which QCZ484 is the first listed.
NCT07543120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07543120 about?
NCT07543120 is a clinical study titled "An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.". The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
What is the current status of trial NCT07543120?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2026-05-07. Estimated completion is 2031-11-30.
What interventions are being tested in trial NCT07543120?
The interventions under investigation include: QCZ484 (DRUG).
Who is sponsoring clinical trial NCT07543120?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07543120's enrollment target sits among peer trials
323 150th of 2000 higher than 1,851 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI